A self injected peptide beat placebo on a daily tasks score in 174 adults

A 12 week randomised trial published in Lancet Neurology in 2023 reported that a synthetic peptide improved how well people with generalised myasthenia gravis managed ordinary daily tasks. The result cleared its threshold comfortably, regulators in three regions accepted it, and the honest description of what it establishes is still narrower than the approvals suggest [1][3].

The disease and the target

Generalised myasthenia gravis is an autoimmune disease in which the body makes antibodies against the receptors that carry the signal from nerve to muscle. Muscles tire quickly and unpredictably: eyelids droop, chewing and swallowing become hard work, breathing can be affected. Most patients carry antibodies against the acetylcholine receptor, and those are the patients this trial enrolled [1].

The drug, zilucoplan, is a macrocyclic peptide, meaning a short chain of amino acids joined into a ring so that it holds its shape and survives longer in the body. It blocks complement component 5, one step in a chain of proteins the immune system uses to attack cells it has marked. Blocking that step is meant to stop the damage at the nerve to muscle junction. It is given as an injection under the skin that a patient does at home each day [1][3].

How the trial was run

RAISE was randomised, double blind and placebo controlled, run at 75 sites across Europe, Japan and North America. Of 239 people screened, 174 were enrolled and assigned by chance: 86 to the peptide and 88 to a matching inactive injection, for 12 weeks. Entry required a level of disability on two standard scales, so nobody in the trial had mild disease only [1].

The main measurement was the change at week 12 in the Myasthenia Gravis Activities of Daily Living score, an eight item questionnaire on things like talking, chewing, breathing and lifting the head, where a higher score means more difficulty. It is a patient reported measure, which is a strength, since it records what the person actually experiences, and a weakness, since it depends on the person not knowing which group they are in [1].

What it found

Scores fell by an average of 4.39 points in the peptide group and 2.30 points on placebo. The difference was 2.09 points, with a range of statistical uncertainty from 0.95 to 3.24 and a P value of 0.0004. The placebo group improving by more than two points on its own is worth noticing: it is a reminder of how much movement a trial of this kind records before any drug is counted [1].

Side effects occurred in 77 percent of the peptide group and 70 percent of the placebo group, most commonly bruising at the injection site, in 16 percent against 9 percent. Serious side effects and serious infections were similar in the two groups. One person died in each group; neither death was judged related to the study drug [1].

What happened after 12 weeks

People who finished the trial could enter an open continuation study called RAISE-XT, in which everyone received the peptide and everyone knew it. An interim analysis of 200 patients, published in 2024, reported that improvement continued to week 24 and held to week 60, and that people who had been on placebo improved within a week of switching [2].

An open continuation is the usual way to gather long term safety information and it cannot function as evidence of benefit. There is no comparison group, everyone knows what they are receiving, and only people who did well enough to continue are in it. In this one, 94 percent of patients reported some side effect, the most common being a worsening of the disease itself, in 26 percent [2].

A subgroup worth reading carefully

A prespecified analysis published in 2025 split the trial by whether patients had previously received immunoglobulin treatment or plasma exchange. The 54 who had not were less severely affected and had been diagnosed more recently. Their scores fell 4.22 points against 2.61 on placebo, against 4.93 against 2.94 in the group with previous treatment. The authors read this as support for using the drug earlier [4].

It is a descriptive analysis of subgroups within a trial that was sized for its whole population, so it generates a question rather than answering one. Fifty four people split across two groups is a small number to carry a conclusion about when to start a treatment.

What is missing from the record

Several new treatments for this disease were approved within a few years of each other, working through different mechanisms. None has been compared against another in a randomised trial. Every comparison currently available is indirect, drawn from separate trials with different patients and different entry criteria, which is the weakest form of evidence about which option suits whom [1][3].

The trial was funded by UCB Pharma, which develops the drug, and many of its investigators report consulting relationships with that company and with the makers of competing treatments. The paper states all of it. Approvals followed in Japan in September 2023, the United States in October 2023 and the European Union in December 2023 [1][3].

What would settle it

Head to head randomised trials against the other approved options, follow up long enough to describe what happens over years rather than one, and a blinded measure of daily function that does not depend on a person guessing their group. A 2.09 point difference over 12 weeks in 174 people is a real finding, reported carefully. It is a starting point in a record that is still thin [1][2][4].